P
MYGN icon

Pitcairn’s Myriad Genetics MYGN Stock Holding History

Pitcairn’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-41,751
Closed -$981K – 478
2013
Q3 		$981K Sell
41,751
-487
-1% -$13.8K 0.12% 145
2013
Q2 		$1.14M Buy
+42,238
New +$1.22M 0.15% 132

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LCG
Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pitcairn's MYGN Position: Q4 2013 in Review

Pitcairn sold out of Myriad Genetics (MYGN) in Q4 2013, closing a stake of 41,751 shares — an estimated $981K sold.

Pitcairn first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $1.14M in Q2 2013. 270 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

  • Pitcairn reported no remaining Myriad Genetics position as of Q4 2013 after selling out during the quarter.
  • Pitcairn sold 41,751 Myriad Genetics shares in Q4 2013, an estimated $981K.
  • Pitcairn first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
  • Pitcairn's Myriad Genetics position peaked at $1.14M in Q2 2013.
  • 270 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Pitcairn's 13F filing for Q4 2013, filed 12 Feb 2014.